Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Harvard Business School

Last Updated: January 31, 2023

Details for Patent: 7,967,011

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions

Which drugs does patent 7,967,011 protect, and when does it expire?

Patent 7,967,011 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-one patent family members in twenty-four countries.

Summary for Patent: 7,967,011
Title:Inhalation device
Abstract: Actuator for an inhaler for delivering medicament by inhalation, having a mouthpiece for guiding medicament to the mouth of a user; and a removable protection cap for the mouthpiece. The cap is secured to the mouthpiece by a cap retaining member that engages a mating recess in the mouthpiece outer periphery. The cap includes at least one release button arranged to provide an elastic deformation of the cap inner periphery that disengages the cap retaining member from the recess.
Inventor(s): Hodson; Darren (Shropshire, GB), Rasmussen; Jorgen (Struer, DK)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:11/346,558
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,967,011
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 7,967,011

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-001 Jul 21, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 AB RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 7,967,011

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9704185Nov 14, 1997

International Family Members for US Patent 7,967,011

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1183699 See Plans and Pricing
Australia 1266799 See Plans and Pricing
Australia 728125 See Plans and Pricing
Australia 750351 See Plans and Pricing
Brazil 9814139 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.